B&L exec sanctioned
This article was originally published in The Tan Sheet
Executive Summary
President & CEO Ronald Zarrella will "forfeit any annual incentive bonuses for 2002, of which $1.1 mil. was guaranteed under his employment agreement," due to misrepresentation on his resume that he received an MBA (1"The Tan Sheet" Oct. 28, 2002, p. 13). In an 2Oct. 29 letter, Bausch & Lomb's Board of Directors does not accept his resignation, noting "we continue to believe [Zarrella is] the right person to carry on the resurgence of the company"...
You may also be interested in...
Sales & Earnings In Brief
Perrigo: Vitamin sales rose 6% in fiscal Q1, outpacing gains in the overall market (2%) and store brands (5%), private labeler says, citing IRI data during Oct. 24 analysts call. "Led by bone health and women's health products, we continued to hold our own in a weak market," Exec VP & CFO Douglas Schrank asserts. Cough/cold/allergy sales gained 9% compared to overall market (up 1%), store brands (down 1%). Company expects negative impact in fiscal Q3 from launch of OTC loratadine (Schering-Plough's Claritin) by other companies, but positive turn in Q1 of fiscal 2004 with its own loratadine offering. Perrigo does not hold "first-to-file" status for any generic loratadine dosage form. First quarter sales fell 1.8% to $213.2 mil., due in part to difficult comparison to year-ago sell-in of famotidine. Net income jump of 52.9% to $20 mil. attributed to manufacturing efficiencies, improved pricing, vitamin settlement proceeds, 1Perrigo press release says...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.